DexCom (NASDAQ:DXCM) had its price target raised by UBS Group from $160.00 to $185.00 in a report issued on Thursday, Stock Target Advisor reports. The firm presently has a “neutral” rating on the medical device company’s stock. UBS Group’s price objective points to a potential downside of 5.89% from the stock’s previous close.
DXCM has been the topic of several other research reports. Robert W. Baird reiterated an “outperform” rating and issued a $240.00 target price (up previously from $195.00) on shares of DexCom in a research note on Thursday. Guggenheim upgraded shares of DexCom from a “neutral” rating to a “buy” rating in a research note on Thursday. Jefferies Financial Group upped their target price on shares of DexCom from $180.00 to $200.00 and gave the stock a “buy” rating in a research note on Thursday. Stifel Nicolaus assumed coverage on shares of DexCom in a research report on Tuesday, October 22nd. They set a “buy” rating and a $190.00 price objective on the stock. Finally, Oppenheimer increased their price objective on shares of DexCom from $180.00 to $205.00 in a research report on Thursday. Five analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $190.67.
Shares of NASDAQ DXCM traded up $1.88 during midday trading on Thursday, hitting $196.58. The stock had a trading volume of 77,631 shares, compared to its average volume of 651,959. The business’s 50 day moving average is $154.75 and its 200-day moving average is $145.88. The company has a market cap of $14.00 billion, a P/E ratio of 656.87 and a beta of 0.64. DexCom has a 52 week low of $105.05 and a 52 week high of $200.80. The company has a quick ratio of 5.64, a current ratio of 6.05 and a debt-to-equity ratio of 1.56.
DexCom (NASDAQ:DXCM) last issued its earnings results on Wednesday, November 6th. The medical device company reported $0.65 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.45. The firm had revenue of $396.30 million for the quarter, compared to the consensus estimate of $348.99 million. DexCom had a negative net margin of 13.96% and a positive return on equity of 10.41%. The business’s revenue was up 48.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.17 earnings per share. As a group, analysts expect that DexCom will post 0.94 EPS for the current fiscal year.
In related news, Director Nicholas Augustinos sold 1,208 shares of the firm’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $145.49, for a total transaction of $175,751.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Steven Robert Pacelli sold 1,532 shares of the firm’s stock in a transaction on Monday, September 23rd. The shares were sold at an average price of $155.47, for a total transaction of $238,180.04. Following the transaction, the executive vice president now directly owns 66,821 shares of the company’s stock, valued at $10,388,660.87. The disclosure for this sale can be found here. Over the last three months, insiders sold 104,014 shares of company stock valued at $16,183,576. Corporate insiders own 1.80% of the company’s stock.
Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC grew its position in shares of DexCom by 9.9% in the 2nd quarter. FMR LLC now owns 10,824,306 shares of the medical device company’s stock worth $791,799,000 after buying an additional 978,898 shares during the last quarter. Janus Henderson Group PLC lifted its stake in DexCom by 29.2% during the 3rd quarter. Janus Henderson Group PLC now owns 8,819,825 shares of the medical device company’s stock valued at $431,510,000 after acquiring an additional 1,991,094 shares during the period. Vanguard Group Inc lifted its stake in DexCom by 11.5% during the 3rd quarter. Vanguard Group Inc now owns 7,942,861 shares of the medical device company’s stock valued at $1,136,147,000 after acquiring an additional 816,247 shares during the period. Vanguard Group Inc. lifted its stake in DexCom by 3.4% during the 2nd quarter. Vanguard Group Inc. now owns 6,821,102 shares of the medical device company’s stock valued at $498,963,000 after acquiring an additional 224,808 shares during the period. Finally, Artisan Partners Limited Partnership lifted its stake in DexCom by 6.3% during the 4th quarter. Artisan Partners Limited Partnership now owns 6,808,715 shares of the medical device company’s stock valued at $406,480,000 after acquiring an additional 403,793 shares during the period. 96.19% of the stock is owned by institutional investors.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.